71866 Federal Register / Vol. 88, No. 200 / Wednesday, October 18, 2023 / Notices 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Healthcare Research and 

Quality 

Supplemental Evidence and Data 

Request on Updating the Framework 

for AHRQ’s National Healthcare Quality 

and Disparities Report (NHQDR) 

AGENCY: Agency for Healthcare Research 

and Quality (AHRQ), HHS. 

ACTION: Request for Supplemental 

Evidence and Data Submission. 

SUMMARY: The Agency for Healthcare 

Research and Quality (AHRQ) is seeking 

scientific information submissions from 

the public. Scientific information is 

being solicited to inform our review on 

Updating the Framework for AHRQ’s 

National Healthcare Quality and 

Disparities Report (NHQDR), which is 

currently being conducted by the 

AHRQ’s Evidence-based Practice 

Centers (EPC) Program. Access to 

published and unpublished pertinent 

scientific information will improve the 

quality of this review. 

DATES: Submission Deadline on or 

before November 17, 2023. 

ADDRESSES: 

Email submissions: epc@

ahrq.hhs.gov. 

Print submissions: 

Mailing Address: Center for Evidence 

and Practice Improvement, Agency for 

Healthcare Research and Quality, 

ATTN: EPC SEADs Coordinator, 5600 

Fishers Lane, Mail Stop 06E53A, 

Rockville, MD 20857. 

Shipping Address (FedEx, UPS, etc.): 

Center for Evidence and Practice 

Improvement, Agency for Healthcare 

Research and Quality, ATTN: EPC 

SEADs Coordinator, 5600 Fishers Lane, 

Mail Stop 06E77D, Rockville, MD 

20857. 

FOR FURTHER INFORMATION CONTACT: 

Kelly Carper, Telephone: 301–427–1656 

or Email: epc@ahrq.hhs.gov. 

SUPPLEMENTARY INFORMATION: The 

Agency for Healthcare Research and 

Quality has commissioned the 

Evidence-based Practice Centers (EPC) 

Program to complete a review of the 

evidence for Updating the Framework 

for AHRQ’s National Healthcare Quality 

and Disparities Report (NHQDR). AHRQ 

is conducting this review pursuant to 

Section 902 of the Public Health Service 

Act, 42 U.S.C. 299a. 

The EPC Program is dedicated to 

identifying as many studies as possible 

that are relevant to the questions for 

each of its reviews. In order to do so, we 

are supplementing the usual manual 

and electronic database searches of the 

literature by requesting information 

from the public (e.g., details of studies 

conducted). We are looking for studies 

that report on Updating the Framework 

for AHRQ’s National Healthcare Quality 

and Disparities Report (NHQDR). The 

entire research protocol is available 

online at: https://

effectivehealthcare.ahrq.gov/products/ 

updating-framework/protocol. 

This is to notify the public that the 

EPC Program would find the following 

information on Updating the Framework 

for AHRQ’s National Healthcare Quality 

and Disparities Report (NHQDR) 

helpful: 

D A list of completed studies that 

your organization has sponsored for this 

topic. In the list, please indicate 

whether results are available on 

ClinicalTrials.gov along with the 

ClinicalTrials.gov trial number. 

D For completed studies that do not 

have results on ClinicalTrials.gov, a 

summary, including the following 

elements, if relevant: study number, 

study period, design, methodology, 

indication and diagnosis, proper use 

instructions, inclusion and exclusion 

criteria, primary and secondary 

outcomes, baseline characteristics, 

number of patients screened/eligible/ 

enrolled/lost to follow-up/withdrawn/ 

analyzed, effectiveness/efficacy, and 

safety results. 

D A list of ongoing studies that your 

organization has sponsored for this 

topic. In the list, please provide the 

ClinicalTrials.gov trial number or, if the 

trial is not registered, the protocol for 

the study including, if relevant, a study 

number, the study period, design, 

methodology, indication and diagnosis, 

proper use instructions, inclusion and 

exclusion criteria, and primary and 

secondary outcomes. 

D Description of whether the above 

studies constitute ALL Phase II and 

above clinical trials sponsored by your 

organization for this topic and an index 

outlining the relevant information in 

each submitted file. 

Your contribution is very beneficial to 

the Program. Materials submitted must 

be publicly available or able to be made 

public. Materials that are considered 

confidential; marketing materials; study 

types not included in the review; or 

information on topics not included in 

the review cannot be used by the EPC 

Program. This is a voluntary request for 

information, and all costs for complying 

with this request must be borne by the 

submitter. 

The draft of this review will be posted 

on AHRQ’s EPC Program website and 

available for public comment for a 

period of 4 weeks. If you would like to 

be notified when the draft is posted, 

please sign up for the email list at: 

https://

www.effectivehealthcare.ahrq.gov/ 

email-updates. 

The review will answer the following 

questions. This information is provided 

as background. AHRQ is not requesting 

that the public provide answers to these 

questions. 

Guiding Questions (GQ) 

GQ1. Which frameworks have been 

developed or are used for quality of 

care? 

• What settings, populations, and 

intended use were the frameworks 

developed for? 

• How are the framework domains 

defined? 

• In what context have these 

frameworks been used? 

• How do these frameworks intersect 

with levers and tools available to federal 

and state governments? 

• How are the frameworks and 

domains similar or different from the 

2010 NASEM framework? 

GQ2. How should the 2010 NASEM 

framework and its domains be updated? 

• How would existing AHRQ NHQDR 

measures be reorganized in the updated 

framework and domains? 

• Are there available measures for 

new framework domains? 

Æ Describe measures in terms of their 

definition, population, years available, 

geographic representation, data sources, 

and supporting evidence. 


ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 88, No. 200 / Wednesday, October 18, 2023 / Notices 71867 

CRITERIA FOR INCLUSION/EXCLUSION OF STUDIES IN THE REVIEW

Domain Inclusion Exclusion 

Population .................. • Publications that address quality of care indicators, criteria, or benchmarks. We will 

accept the authors’ definition of quality of care. Quality indicators may include care 

processes-related measures (e.g., follow-up post discharge, continuity of care, 

medication errors), heath services utilization measures (e.g., hospital readmission, 

emergency department visit), care satisfaction (e.g., patient satisfaction, care needs 

met, trust in care provider), or health outcomes (e.g., mortality, physical functional 

status, mental functioning, quality of life) used as quality indicators. Publications 

that do not address quality of care in detail but include quality of care and health 

equity in a framework will also be eligible. Care disparities may either address differences in provided health services, focus on care services or health outcomes of 

priority populations.

• Publications not addressing 

quality of care and publications not mentioning quality of 

care nor health equity as a 

central feature of a framework. 

Concept ..................... • Publications that include a figure or detailed description of a framework of quality of 

care or care disparities; frameworks may use the format of a logic model, analytic 

framework, conceptual model, or other conceptualizations of quality of care.

• Publications citing existing 

frameworks without further 

conceptual contribution to the 

framework and publications 

describing only the need of 

quality of care measures. 

Context ...................... • Healthcare, specifically healthcare delivery organizations .......................................... • Studies in contexts outside of 

healthcare or not specific to 

healthcare. 

Other limiters ............. • Reports published in English-language, journal manuscripts, trial records, and gray 

literature in the public domain from the outlined sources.

• Data reported in abbreviated 

format (e.g., conference abstracts) will be excluded; 

studies not published in 

English 

• Systematic reviews will be retained for reference mining. 

Dated: October 12, 2023. 

Marquita Cullom, 

Associate Director. 

[FR Doc. 2023–22915 Filed 10–17–23; 8:45 am] 

BILLING CODE 4160–90–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

Pursuant to section 5 U.S.C. 

Section1009(d), notice is hereby given 

of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended, and the Determination of 

the Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, CDC, pursuant to Public Law 

92–463. The grant applications and the 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Disease, 

Disability, and Injury Prevention and 

Control Special Emphasis Panel (SEP)- 

CE24–013, Research Grants to Identify 

Effective Community-Based Strategies 

for Overdose Prevention (R01). 

Date: March 12–13, 2024. 

Time: 8:30 a.m.–5 p.m., EDT. 

Place: Web Conference. 

Agenda: To review and evaluate grant 

applications. 

For Further Information Contact: 

Aisha L. Wilkes, M.P.H., Scientific 

Review Officer, National Center for 

Injury Prevention and Control, Centers 

for Disease Control and Prevention, 

4770 Buford Highway NE, Mailstop 

S106–9, Atlanta, Georgia 30341, 

Telephone: (404)639–6473; Email: 

AWilkes@cdc.gov. 

The Director, Office of Strategic 

Business Initiatives, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention. 

[FR Doc. 2023–23006 Filed 10–17–23; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

Pursuant to 5 U.S.C. 1009(d), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended, and the Determination of 

the Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, CDC, pursuant to Public Law 

92–463. The grant applications and the 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Disease, 

Disability, and Injury Prevention and 

Control Special Emphasis Panel (SEP)— 

CE24–029, Grants to Support New 

Investigators in Conducting Research 

Related to Preventing Interpersonal 

Violence Impacting Children and Youth. 

Date: March 19, 2024. 

Time: 8:30 a.m.–5 p.m., EDT. 

Place: Web Conference. 

Agenda: To review and evaluate grant 

applications. 


ddrumheller on DSK120RN23PROD with NOTICES1